Why One Positive Lyme Test Is Not a Diagnosis: Two-Tier Serology Explained

A reactive result opens a question; it does not answer it#

One positive Lyme antibody test does not, by itself, mean you have Lyme disease. The reason is structural. The CDC recommends a two-step (two-tier) serologic process in which a reactive first test simply routes the sample to a second confirmatory test. The first result is a flag, not a finding. Understanding why the algorithm is built this way explains most of the confusion you meet when a lab report says "positive."

Key points#

• Lyme serology detects antibodies the immune system makes against Borrelia burgdorferi, not the bacterium itself.
• A single reactive assay is designed to be confirmed by a second test before it counts as positive.
• Antibodies lag the infection, so tests can be falsely negative in the first four to six weeks.
• Titers can stay elevated for months to years after successful treatment, so serology cannot confirm cure.
• Testing people with no realistic chance of tick contact produces mostly false positives.

What the test is actually measuring#

The starting point that clears up the most misunderstanding is this: these assays do not look for the Lyme bacterium. They look for the antibodies your own immune system produces in response to it. That single fact drives every quirk that follows. Because antibodies take time to appear, an early test can miss a real infection. Because antibodies linger, a later test can stay positive after the infection is gone. And because antibody production is never perfectly specific to one organism, some healthy people react without ever having been infected. Serology is a measure of immune memory. It is not a measure of live bacteria in your blood.

The two-step design and the reason it exists#

The CDC's testing guidance describes a sequential process that runs FDA-cleared assays on the same blood sample. The logic is deliberately gated. If the first test is negative, testing stops there and the result is reported as negative. Only a positive or equivocal first result moves forward to the second test. No single reactive assay is meant to stand on its own.

Standard and modified two-tier testing#

In standard two-tier testing, the first step is an enzyme immunoassay (EIA) and the second is a Western blot, also called an immunoblot, which reports separate IgM and IgG bands scored against defined criteria.

Since 2019, a modified two-tier testing option has been available. In July 2019 the FDA cleared several assays allowing a second EIA to substitute for the Western blot, and the CDC endorsed the change in an August 2019 MMWR notice. Its wording was precise: serologic assays that use an EIA rather than a western immunoblot in a two-test format are acceptable alternatives when the FDA has cleared them for that use. Running two EIAs in sequence is faster and easier to read than a blot, which is why many laboratories have adopted it. The underlying logic does not change. Whichever second test is used, its job is to filter out the non-specific reactivity a single EIA can generate.

Why the test trails early infection#

Antibodies build up over days to weeks, and the CDC notes that serologic assays may be falsely negative during the first four to six weeks after infection. That window is exactly when many people first notice a tick bite or an early rash, so the test is at its least reliable at the moment you are most likely to ask for it. Sensitivity in early localized disease is low, and the expanding rash called erythema migrans often appears before your antibodies become measurable.

This is why an early rash matters more than an early blood test. Erythema migrans in a person with a plausible chance of tick contact is grounds for treatment on its own, and a negative test taken that early does not rule the disease out. As an untreated infection spreads, sensitivity climbs, and by the later stages two-tier testing detects the large majority of true cases.

There is a mirror-image trap at the other end. Prompt antibiotic treatment can blunt the antibody response, so the CDC cautions that patients treated early may be less likely to seroconvert. You can be correctly treated and still never mount a strongly positive test.

The 30-day rule for IgM#

IgM antibodies appear early in an immune response and cross-react readily with unrelated triggers. The CDC's interpretation guidance is direct about the consequence: a positive IgM result should be disregarded if the patient has been ill for more than 30 days. If you have had weeks or months of vague symptoms and test IgM-positive but IgG-negative, the algorithm says that result does not support a Lyme diagnosis. Reading a lone IgM band as proof of infection is one of the most common ways a non-diagnosis gets mistaken for a diagnosis.

Why a positive can outlast the infection#

Because serology reflects immune memory, a positive result does not switch off when the bacteria are cleared. The CDC's reporting and interpretation guidance is explicit that once titers rise they can stay elevated for months to years and cannot be used to judge whether treatment worked. If you were infected and successfully treated, you may keep testing positive long afterward. Repeating serology as a "test of cure," or reading a later positive as a relapse, asks the assay to do something it cannot. There is no serologic test of cure in Lyme disease.

Why testing low-risk patients backfires#

Here is where pretest probability decides everything. No antibody test is perfectly specific, so a small fraction of people who were never infected will still test positive. When the group tested has a genuine chance of contact, recent tick contact, a compatible illness, or time spent in an area where Lyme is common, most positives reflect real infection. When the same test is aimed at people with nonspecific fatigue and no realistic risk factors, the pool of true cases is tiny and false positives can outnumber them. The two-tier structure raises specificity precisely to fight this, but it cannot repair a test ordered for the wrong person. Used as a broad screen for undifferentiated symptoms, Lyme serology tends to create confusion rather than resolve it.

The bottom line#

A Lyme diagnosis rests on three things read together: a realistic chance of tick contact, compatible clinical findings, and correctly interpreted two-tier serology. A single reactive band, an IgM result read past its 30-day window, or a positive left over from an old and treated infection is a different matter entirely. The algorithm was built so that no single number ever has to carry the diagnosis by itself.